Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.

Avalo Therapeutics, Inc.

Avalo Therapeutics | 2,687 followers on LinkedIn. Innovation driven by compassion. | Avalo Therapeutics is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize targeted therapeutics for patients with significant unmet clinical need. 

Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased probability of success.  

We are rapidly advancing a rich pipeline with broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.

Biotech Digital Landscape Leader | Digital and Transformation Leadership from Startup to Fortune 500 Company

Yingping Zhang

CEO, Independent Director, Physician-Scientist

Garry Neil

Chief Executive Officer at Clinical ink

Jonathan Goldman, MD MBA

Senior Director, Quality Assurance - Avalo Therapeutics

Tammy Updegrove

Avalo Therapeutics

Avalo is seeking a contractor to join our Clinical Operations team. If you have experience in clinical trials and a passion for advancing treatments through clinical development, check out the job post below! #clinicaltrials #development #immunology #clinops #contractor #biotech

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa https://lnkd.in/eJGtYVz4

We're #hiring a new Administrative Assistant in Wayne, Pennsylvania. Apply today or share this post with your network.

Avalo Therapeutics is pleased to welcome Mittie Doyle to our team as Chief Medical Officer. Mittie is a proven physician scientist and senior R&D leader with over 20 years of clinical development experience in the pharmaceutical/biotech industry and academia. Her expertise will be invaluable as we advance our portfolio, including initiating the Phase 2 program for AVTX-009, and continuing to pursue our mission to deliver novel therapeutics for patients with significant unmet clinical need. Welcome, Mittie! Read the full announcement here: https://bit.ly/4c27nzb

We're #hiring for a contract Clinical Operations Manager. Click below to apply today or share this post with your network! #clinical #clinicaltrials #contractor #clinops #clinicalstudy #development #biotech #therapeutics

Avalo Therapeutics is delighted to welcome Paul Varki to our team as Chief Legal Officer. Paul brings over 20 years of experience providing counsel in the pharmaceutical and biotech industry. His appointment underscores our commitment to strengthening our core leadership team and his deep industry experience and legal expertise will enhance our strategic and operational capabilities for future growth. Read the full announcement here: https://bit.ly/4eG99s3

We're #hiring a new Associate Director, Product Supply in Wayne, Pennsylvania. Click below to apply today or share this post with your network! #clinicalsupply #biotechnology #newjobalert #hiring #joinourteam #avalo

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million https://lnkd.in/ePTuMRun

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 13, 2024 8:06 AM	7346cefc
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 13, 2024 8:06 AM	63d0746a
crunchbase trigger	general	Nov 13, 2024 8:06 AM	d59b87ae
crunchbase profile	general
li profile	general	Nov 13, 2024 8:06 AM	f8a61106
translate crunchbase fundingrounds	general
peers	general	Nov 13, 2024 8:06 AM	53a95430
news basic	general	Nov 13, 2024 8:06 AM	1dd16996
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AVALOTX

Avalo Therapeutics, Inc.

Last Close

10.90

21/11 21:00

Market Cap

12.97M

Beta: -

Volume Today

88.35K

Avg: -